Loss-of-function screening to identify miRNAs involved in senescence: tumor suppressor activity of miRNA-335 and its new target CARF

Yue Yu1,2,*, Ran Gao1,3,*, Zeenia Kaul4, Ling Li1,2, Yoshio Kato1, Zhenya Zhang2, Joanna Groden4, Sunil C Kaul1 & Renu Wadhwa1

Significance of microRNAs (miRs), small non-coding molecules, has been implicated in a variety of biological processes. Here, we recruited retroviral insertional mutagenesis to obtain induction of an arbitrary noncoding RNAs, and coupled it with a cell based loss-of-function (5-Aza-2′-deoxycytidine (5Aza-dC)-induced senescence bypass) screening system. Cells that escaped 5-Aza-dC-induced senescence were subjected to miR-microarray analysis with respect to the untreated control. We identified miR-335 as one of the upregulated miRs. In order to characterize the functional significance, we overexpressed miR-335 in human cancer cells and found that it caused growth suppression. We demonstrate that the latter accounted for inhibition of 5-Aza-dC incorporation into the cell genome, enabling them to escape from induction of senescence. We also report that CARF (Collaborator of ARF) is a new target of miR-335 that regulates its growth suppressor function by complex crosstalk with other proteins including p16INK4A, pRB, HDM2 and p21WAF1.

MicroRNAs (miRs) are a class of highly conserved small non-coding molecules (about 21–25 nucleotides long) that act as gene repressors by either causing their mRNA degradation or translational block. They are transcribed as pri-miRNAs and are subsequently processed into short hairpin structured molecules by Drosha, the double-stranded RNA specific ribonuclease. Their involvement in diverse biological processes ranging from normal development to a variety of pathogenesis has been implicated. Hence, miR profiling has been considered to yield valuable outcomes, not only to understand the regulation of basic biological phenomena but also, in disease, diagnosis, therapy and prognosis1–3.

Cancer is a complex disease. It is regulated by multifaceted network of signaling pathways driven by loss of activities of tumor suppressor proteins, gain of function of oncogenes and several epigenetic mechanisms4–8. Many miRs, including miR-21, miR-143, miR-145, miR-182, have been found as enriched in tumors and shown to possess oncogenic functions7–9. On the other hand, several others including, miRNA-125b, miR-335-5p, and miR-34 family are downregulated in several types of cancers10–14. Recently, it was shown that the tumor suppressor protein p53 regulates miRNA expression and processing, and in turn gets regulated by miRs. Restoration of p53-induced miRs was shown to cause suppression of tumor growth and metastasis in mouse models of cancer suggesting that there is a complex network of miR-p53 interactions in the regulation of p53 activities, its effectors and regulators15–17. Several other tumor suppressor pathways including pRB, PTEN, p16INK4A, BMI and p14ARF
have been shown to be either regulated by miRs or involve them for their activities to implement control on cell proliferation\cite{18-22}. In spite of imperative emerging evidence of the role of several miRs in cancer, the molecular targets and mechanisms remain largely undefined. In addition, a number of miRs have also been characterized to possess both tumor suppressor and oncogenic functions\cite{23-25} warranting molecular insights to their activities in context of cell physiology.

Epigenetic control of cancer has been well-established\cite{6}. Several epigenetic drugs (DNA methyltransferases and histone deacetylase inhibitors) that induce senescence in cancer cells have been in practice in conventional chemotherapy. However, their impact on the miRs and cancer progression remains largely unknown\cite{24}. It was reported that miR-34 and miR-145 were silenced through DNA hypermethylation and were, hence, induced by 5-Aza-dC treatment\cite{25,26}. In the present study, we used a retroviral vector containing GFP reporter to introduce retroviral insertional mutagenesis \cite{27}. Genomic integration of this vector was expected to induce trans-scription of sequences downstream to its integration sites. Based on the fact that more than 98% of the human genomic DNA constitutes protein-noncoding sequences, such random integration of the vector in genome was expected to induce a large variety of miRNAs (referred to as arbitrary miR library). Cells expressing such random library of miRs were subjected to 5-Aza-dC induced senescence for 3–5 days. Whereas untransduced controls showed senescence phenotype, some virus-transduced cells escaped from 5-Aza-dC induced senescence (called loss-of-function/senescence bypass). These cells were subjected to miR-array data analysis with respect to the control (untransduced) cells. Out of several upregulated miRs, we characterized the function of miR-335 in the present study. We report that miR-335 possesses tumor suppression function, mediated, at least in part, by targeting CARF that in turn regulates several cell cycle monitoring proteins including p16\textsuperscript{ink4}, pRb, p53 and p21\textsuperscript{waf1}.

Results and Discussion

Identification of miR-335 in 5Aza-dC induced senescence bypass. A retroviral vector constituting two long terminal repeat (LTR) promoters at 5' and 3' ends of GFP gene was generated in a way that the random integration of this vector in the genome would result into (i) expression of GFP; detected by green fluorescence and (ii) its integration site-dependent arbitrary manipulation of the host cell genome. The latter may yield loss-of-function phenotype due to altered expression of either proteins or the noncoding microRNA regulators. We coupled this system with induction of senescence in human cancer (U2OS) cells by demethylating drug, 5-Aza-dC (Fig. 1A). Cells treated with 5-Aza-dC showed strong induction of cellular senescence. More than 90% of control (virus untransduced) cells showed growth arrest and senescence associated β-gal staining in about 3–5 days. Small colonies appeared in virus-transduced cells at about 4–6 days. These showed green fluorescence, and hence were originated from transduced cells that bypassed senescence by loss of response to 5Aza-dC. The cells were expanded and were subjected to microRNA array with respect to the untransduced and untreated control cells (Fig. 1). We found several miRNAs (miR-101, miR-137, miR-145, miR-335, miR-384, miR-451, miR-545 and miR-558) upregulated in virus-transduced cells that showed resistance to 5-Aza-dC-induced senescence (Fig. 1 and Supplementary Fig. 1A,B). Of note, two of these miRs (miR-145 and miR-335) have been reported to undergo hypermethylation-mediated silencing in a large variety of cancers\cite{25,28}. Hence, their upregulation by 5-Aza-dC induced demethylation was justified. Furthermore, it may also be the result of retroviral insertional mutagenesis\cite{27} (induction of transcription downstream of integration of the virus to cell genome). These data suggested that these miRs are involved in regulation of induction of cellular senescence, proliferation and drug response of cells. In the present study, we aimed to characterize such functions and targets of miR-335.

miR-335 compromises 5-Aza-dC induced senescence by inducing growth suppression. In view of the literature that miR-335 is silenced by hypermethylation in cancer cells\cite{25,28}, we first examined if induction of senescence by 5-Aza-dC involved upregulation of miR-335 expression. Untransduced control cells were treated with 5-Aza-dC. Induction of senescence was tracked by examining the cell morphology and number in control and treated cells. At about 5–6 days post-treatment, treated cell cultures showed senescent morphology and growth arrest, also confirmed by senescent associated β-gal staining (Fig. 1B). Senescent cells were collected and subjected to miR-335 expression analysis. Contrary to our expectation, we found that miR-335 was down-regulated in treated cells (Fig. 1B) suggesting that its upregulation, as detected by miR-array analysis, may have role in escape from senescence. An expression plasmid encoding primary miR-335 was transfected into U2OS cells. Treatment of control or miR-335-transfected cells with 5-Aza-dC and detection of senescent cells by senescence associated β-gal staining revealed that prior upregulation of miR-335 indeed compromised induction of senescence. There was about 50% reduction in the number of SA-β-gal positive cells in miR-335 transfected cells (Fig. 1C). Cell viability analysis also showed that miR-335 transfected cells were less responsive to 5-Aza-dC, particularly at doses higher than 20 μM (Fig. 1D) suggesting that prior upregulation of miR-335 was involved in the escape from 5-Aza-dC induced senescence/growth arrest. Taken together, these data suggested that miR-335 was downregulated in cells that showed senescence upon 5-Aza-dC treatment, and that the overexpression of miR-335 suppressed such effect of 5-Aza-dC.

In order to clarify the mechanism of the role of miR-335 in escape from 5-Aza-dC induced senescence, we considered two possibilities: (i) based on the fact that incorporation of 5-Aza-dC takes place during replication and DNA synthesis, we hypothesized that miR-335 might cause growth arrest of cells and thus do not allow 5-Aza-dC to be incorporated into the genome, and (ii) miR-335 may target genes that are essential for 5-Aza-dC induced growth arrest. We tested the first possibility by analyzing the growth and cell cycle characteristics in control and miR-335 transfected cells. As shown in Fig. 2, the latter were retarded in their growth (A) and showed lower viability in short term (B) as well as long term colony-formation assays (C). Cell cycle analysis revealed increase in number of cells at G0/G1, G2/M and decrease in S phase (Fig. 2D). These data suggested that miR-335 suppressed the growth of cells that may have contributed, at least in part, to escape of cells from 5-Aza-dC induced senescence, as hypothesized above. miR-335 induced suppression of cell growth was also confirmed
by in vivo subcutaneous xenografts of control and miR-335 transfected A549 cells in nude mice (Fig. 2E). We found that the tumor growth of miR-335 overexpressing cells was suppressed as compared to the control cells. In order to investigate the relevance of miR-335 in proliferation rate of cells, we performed its expression analysis in normal and cancer cells. Amongst different cancer cell lines, we found ~5 fold variation in the level of miRNA. Nevertheless, consistent with its above described growth suppression function, miR-335 expression was ~2–4 fold higher in normal fibroblasts as compared to a variety of cancer cells (Fig. 2F). Furthermore, in line with its growth suppression activity in in vitro and in vivo assays, the miR-335 overexpressing cells showed upregulation of p21^{WAF1} (Fig. 3A,B and Supplementary Fig. 2A) and downregulation of CDK4 at protein (Fig. 3C,B and Supplementary Fig. 2B) and mRNA (Fig. 3D) levels. Furthermore, as expected, the growth suppression induced by miR-335 per se (Fig. 2E) was associated with substantial resistance to induction of growth arrest/senescence by 5-Aza-dC (Fig. 3E). As expected, increase in p21^{WAF1} was associated with decrease in E2F5 in miR-335 overexpressing cells (Fig. 3F). Simultaneous knockdown of p21^{WAF1} by shRNA abolished miR-335-induced decrease in E2F5 (Fig. 3G) resulting in recovery, at least in part, from growth suppression caused by miR-335 (Fig. 3H). These data suggested that p21^{WAF1} plays a key effector role in miR-335-induced growth suppression signaling.

Figure 1. Identification of miR-335. Strategy for induction of miR library in human cancer cells and loss-of-function/senescence bypass screening is described (A). The cells infected with bicistronic vector constituting of two promoters and GFP were treated with 5-Aza-dC. Whereas control uninfected cells showed induction of senescence, colonies emerged in the virus harboring cells. These colonies were expanded and pool of colonies was subjected to miR-array analysis with respect to the untransduced control cells. miR array analysis resulted in identification of miR-335 as one of the upregulated miR in cells that escaped 5-Aza-dC-induced senescence. Cells undergoing 5-Aza-dC-induced senescence showed down-regulation of miR-335 (B). Cells overexpressing miR-335 showed resistance to 5-Aza-dC-induced senescence as examined by senescence associated β-gal staining (C) as well as cell viability assays (D).

Effect of miR-335 on p16^{INK4A} and pRB, resulting in compromised 5-Aza-dC-induced senescence. We next considered the second possibility that the miR-335 may target essential genes involved in 5-Aza-dC induced growth arrest. In U2OS cells, p16^{INK4A} (cyclin-dependent kinase inhibitor and tumor suppressor) is known to undergo silencing by hyper-methylation of its promoter29. As expected, 5-Aza-dC treated cells showed induction of p16^{INK4A} (Fig. 4A,B and Supplementary Fig. 2C). Of note, we found that miR-335-transfected cells showed downregulation of 5-Aza-dC-induced p16^{INK4A} protein expression (Fig. 4A) suggesting that miR-335 may target p16^{INK4A} directly/indirectly and hence may account for escape of 5-Aza-dC-induced senescence. Further to confirm, we determined the expression of p16^{INK4A} in control and miRNA-transfected cells by qPCR.
using three sets of primers and, surprisingly, found increase in p16INK4A transcript not only in 5Aza-dC-treated controls, but also miR-335 overexpressing cells (Fig. 4C). These data suggested that the decrease in p16 INK4A protein observed in miR-335 overexpressing cells (Fig. 4A,B) was not due to direct targeting of p16INK4A mRNA by miR-335.

p16INK4A is an established inhibitor of cyclin D-CDK4 complex. The latter phosphorylates retinoblastoma protein resulting in its dissociation from E2F family of proteins that are required for cell cycle progression. Accordingly, decrease in p16INK4A in miR-335 overexpressing cells was expected to result in activated cyclin D-CDK4 complex resulting in increased level of phosphorylated pRB in these cells. We examined the levels of pRB and phospho-pRB and found, contrary to the expected, decrease in phospho-pRB in miR-335 derivatives (As shown in Fig. 4D and Supplementary Fig. 2D). Western blotting with pRb and phospho-pRB specific antibodies also confirmed their downregulation in miR-335 transfected cells (Fig. 4E). qPCR analysis also revealed decrease in pRB transcript in miR-335 overexpressing cells (Fig. 4F) endorsing that miR-335 targets pRB. Such decrease in phospho-pRB was attributed to cause cell cycle retardation and escape of cells from 5-Aza-dC induced senescence. Another study also showed that during differentiation of mouse embryonic stem cells, miR-335 is upregulated and causes downregulation of Oct4-pRB axis and pRB dephosphorylation19. In this report, miR-335 was shown to target pRB directly and specifically targeting a conserved sequence motif in its 3′un-translated region18. However, it was shown to cause consequential activation of p53 tumor suppressor resulting in inhibition of cell proliferation and transformation. Taken together with our findings, it emerged that miR-335 is an important miR that controls cell proliferation by balancing the activities of pRB and p53 tumor suppressor pathways.

miR-335 targets CARF and compromises 5-Aza-dC induced senescence. In light of the information that miR-335 targets pRB and activates p5318, we examined the level of p53 in control and miR-335 transfected cells. As shown in Fig. 5, we found decrease in protein as well as mRNA level of p53 in miR-335 transfected cells (Fig. 5A–C and Supplementary Fig. 2E). The data suggested that miR-335 targets p53 and contributes to
Figure 3. miR-335 overexpression mediated growth suppression involves upregulation of p21\(^{\text{WAFl}}\). miR-335 overexpressing cells showing growth suppression possessed higher level of expression of p21\(^{\text{WAFl}}\) (A, B) and low level of expression of CDK4 (C, B). mRNA expression revealed increased level of p21\(^{\text{WAFl}}\) and decreased level of CDK4 in miR-335 overexpressing cells (D). miR-335 overexpression caused growth suppression per se, and resistance to 5-Aza-dC induced senescence (E). miR-335 overexpressing cells showed downregulation of E2F5 (F) that was abolished by simultaneous knockdown of p21\(^{\text{WAFl}}\) using p21\(^{\text{WAFl}}\) specific shRNA-1 (G). Retardation of cell growth in miR-335 transfected cells was abrogated by shRNA mediated knockdown of p21\(^{\text{WAFl}}\) (H). Scale bars represent 20 μm.
escape of cells from 5-Aza-dC-induced senescence. However, as shown in Fig. 3B, downstream effector of p53, p21WAF1, showed increase in miR-335-overexpressing cells. We examined the HDM2 protein, another downstream effector and antagonist of p53, by immunostaining and Western blotting, and found its elevated level in miR-335-transfected cells (Fig. 5D,E and Supplementary Fig. 2F). These results were also supported by qPCR analysis (Fig. 5F) suggesting that miR-335 may target an upstream inhibitor of HDM2, leading to its increased levels that in turn may contribute to decreased level of p53 in miR-335 transfected cells.

CARF (Collaborator of ARF), a protein that poses two-way control on cell proliferation, has been shown to be an upstream regulator of p5330–32. Whereas its upregulation occurred during replicative and premature senescence, its super-high level was shown to be associated with tumorigenesis and malignant transformation of cancer cells33. It was shown to act as a transcriptional repressor of HDM234. In view of our above findings, we examined CARF-p53-HDM2-p21 axis in miR-335 overexpressing cells. As shown in Fig. 6A–C and Supplementary Fig. 2G, these cells showed down-regulation of CARF at both protein as well as mRNA levels implying that miR-335 targets CARF, and may account for increased level of HDM2 and decreased level of p53 (Fig. 5A,D, respectively). Vector transfected cells did not show decrease either in CARF or in p53 (Supplementary Fig. 1C).

In order to finally resolve whether miR-335 directly targets CARF, p53 and p21WAF1, we performed reporter assays using 3'UTR regions of these genes. As shown in Fig. 7A, we found that CARF, but not p53 and p21WAF1, was the target of miR-335. Of note, target site search for miR-335 on CARF, p53 and p21WAF1 3'UTR gene sequences predicted two sites in CARF (Supplementary Fig. 1D), and none in the p53 and p21WAF1 3'UTR. These data supported our above findings, and excluded p53 and p21WAF1 to be a target of miR-335. This was consistent with the findings of Scarola et al.18 who reported that p53 was not the target of miR-335. Instead, it showed increase that was consequent to decrease in pRB in cells transiently transfected with miR-335. We also found increase in p53 in cells transiently transfected with miR-335 (Supplementary Fig. 1E). However, stable transfections of miR-335 caused decrease in p53 (Fig. 5A–C and Supplementary Fig. 1E) that was attributed to increased
level of HDM2 (Fig. 4D–F) (an established antagonist of p53) that is normally repressed by CARF. Of note, CARF has been shown to act as transcriptional repressor of p21WAFL35 and hence targeting of CARF by miR-335

Figure 5. miR-335 overexpressing cells showed compromised expression of p53. Immunostaining (A) Western blotting (B) and qPCR (C) analyses for p53 showed decreased level of expression in miR-335 overexpressing cells. The transfected cells showed higher level of expression of HDM2; immunostaining (D) Western blotting (E) and qPCR (F) data are shown. Scale bars represent 20 μm.

Figure 6. miR-335 overexpressing cells showed decrease in CARF expression. Immunostaining (A) Western blotting (B) and qPCR (C) analysis for CARF showed decreased level of expression in miR-335 overexpressing cells. Scale bars represent 20 μm.
Figure 7. miR-335 targets CARF, not p53. 3′UTR reporter assay for CARF, p53 and p21 in control and miR-335 overexpressing cells showed that miR-335 targets CARF (A). p21WAF1 promoter reporter assay in control and miR-335 transfected cells showed upregulation of p21 (B). Increase in p21WAF1 occurred in p53−/− cells and was hence independent to that of p53 (C). Overexpression of CARF compromised miR-335 induced downregulation of p21WAF1 (D). siRNA-mediated knockdown of CARF strengthened the miR-335 induced increase in p21WAF1 (E). Schematic presentation of miR-335 targets as resolved in this study. miR-335 targets CARF and pRB (F). Dominant pathways are shown by solid lines. Upregulation and downregulations of proteins are shown by upward and downward arrows. Decrease in CARF caused (i) increase in HDM2 resulting in decrease in p53 and (ii) increase in p21WAF1 causing decrease in CDK4 and E2F5 (as shown in Fig. 3B,F, respectively) resulting in delay in cell cycle progression (shown in Figs 1 and 2).
also accounted for upregulation of p21\(^{\text{WAF1}}\) (Fig. 3A,B) that occurred contrary to the decreased level of expression of p53, p21\(^{\text{WAF1}}\) promoter luciferase reporter assays in control and miR-335-transfected cells also showed increase in p21\(^{\text{WAF1}}\) reporter activity in the latter (Fig. 7B). Furthermore, we determined that this increase in p21\(^{\text{WAF1}}\) was independent to that of p53 by using p53−/− cells (Saos-2). As shown in Fig. 7C, miR-335–transfected cells showed decrease in CARF and increase in p21\(^{\text{WAF1}}\) suggesting that miR-335 targets CARF and caused increase in p21\(^{\text{WAF1}}\) independent to that of p53. In order to further validate, we reconstituted CARF in miR-335 transfected cells and found that an overexpression of CARF abolished the increase in p21\(^{\text{WAF1}}\) transfected cells (Fig. 7D).

siRNA-mediated CARF knockdown, on the other hand, potentiated the effect of miR-335 on p21\(^{\text{WAF1}}\) expression (Fig. 7E).

CARF is an essential cell proliferation-regulatory protein that is upregulated during replicative and stress-induced senescence. Suppression of CARF induced aneuploidy, DNA damage and mitotic catastrophe in neuroblastoma46, Bcl-w and specificity protein 1 (SP1) in gastric cancer14,47 and ZEB2 in colorectal cancer48. CARF silencing by shRNA has earlier been shown to cause tumor suppression in nude mice tumor for-

In agreement with our findings on identification of miR-335 in retrovirus-induced arbitrary manipulation of genome and cell based functional screening of miRs involved in escape from 5-Aza-dC treatment, Gao et al.33 and Dohi et al.28 have also reported that miR-335 expression was increased after 5-Aza-dC treatment, endorsing its regulation by methylation. Deletion and hypermethylation of microRNA-335 locus (7q32.2) has been reported in patient-derived metastatic breast and ovarian cancer cells. Its restoration inhibited migration via targeting extracellular matrix glycoprotein (Tenascin-C) involved in cell migration37, and was shown to induce premature senescence in young mesangial cells via downregulation of SOD2 and Txnrd2 with a concomitant increase in reactive oxygen species (ROS)38. It was also suggested as a strong inhibitor of tumor re-initiation 39. Downregulation of miR-335 in a variety of tumors and its tumor suppressor function has recently been emerged in several independent studies that have also demonstrated its multiple gene targets60,61. These include RANKL and IGF-1R in SCLC42, BRCA1-regulatory cascade and c-Met protein in breast cancers 13, OCT4 in pancreatic cancer62, Pax6 in glioma63, Bcl-w or BCL2L2 in the ovarian cancer45, RUNX2 in hMSCs40, ROCK1 and MAPK1 in neuroblastoma39, Bcl-w and specificity protein 1 (SP1) in gastric cancer44,47 and ZEB2 in colorectal cancer48. We demonstrated that CARF is a new target of miR-335 that mediates its tumor suppressor function (Fig. 7F).

Materials and Methods

Cell culture and drug treatment. Human osteosarcoma (U2OS and Saos-2), cervical carcinoma (HeLa), breast adenocarcinoma (MCFC7 and MDA-MB-231), lung carcinoma (A549 and H1299) and normal human fibroblasts (TIG, MRC5 and WI38) were purchased from Japanese Collection of Research Bioresources (JCRB, Japan) and cultured in Dulbecco’s Modified Eagle’s Medium (DMEM; Gibco BRL, Grand Island, NY, USA) supplemented with 10% (v/v) fetal bovine serum (Gibco BRL), and 1% (v/v) penicillin/streptomycin in the presence of 5% CO\(_2\) at 37 °C as described earlier49,50. Cells were treated with 20μM of 5-Aza-2′-deoxycytidine (5-Aza-dC) (Sigma-Aldrich, St. Louis, MO, USA) for 72–96 h and subjected to the following in vitro assays.

Retrovirus infection. Exogenous expression of CARF was carried out using a retroviral carrier of GFP-tagged CARF that was cloned into a pCX4neo vector as previously described31. All the transfections were performed with FuGENE6 (Roche Applied Sciences, Basel, Switzerland), following the manufacturer’s protocol. Culture medium was replaced with fresh media 24 h after transfection. The viral stock was diluted 1/100, supplemented with 8μg/ml polybrene and used to infect cells for the generation of CARF overexpressing cells. Selection of infected clones was performed with medium containing G418 (500–900μg/ml) after 18–24 h to obtain stable GFP–CARF expressing cell lines.
RNA interference (RNAi) and plasmid transfections. The synthesis and sequences of CARF siRNAs are described elsewhere. Briefly, for annealing of siRNAs, 20 μM of each control or target sense and antisense strand were incubated in annealing buffer (100 mM potassium acetate, 30 mM HEPES-KOH at pH 7.4 and 2 mM magnesium acetate) for 1 min at 90 °C followed by 1 h at 37 °C. siRNA duplexes were carried out using lipofectamine RNAiMAX (Invitrogen, Carlsbad, CA, USA), following the manufacturer’s protocol. Two p21 shRNA vectors (target sites, shRNA-1: agaggtgattgaattcaac and shRNA-2: atagatttctatcatttca) were used as described earlier. The expression or shRNA vectors were transfected into cells using X-tremeGENE 9 DNA transfection reagent (Roche), following the manufacturer’s protocol.

Induction of arbitrary miR library and screening for miRNAs involved in escape from 5Aza-dC induced senescence. To construct a retroviral vector pMXGbu, a short linker with 5′-gaattAGCGGAG-GACAGTACTCCGATCCGGAGACATGTACTCCGTcgc -3′ was inserted between EcoRI and SalI sites of pMX-CRGb by removing CMV-RFP cassette. Upon transduction, the upstream LTR of the vector drives GFP-Bsd fusion gene and the downstream LTR initiates random transcription resulting into retroviral insertional mutagenesis and thus arbitrary alteration of gene expression. The transduced cells were selected in blasticidin (10 μg/ml) supplemented medium and were then subjected to 5Aza-dC (20 μM) for 3–5 days. The cells were subsequently harvested to prepare total RNA (RNeasy Plus Mini Kit (QiAGEN)).

miRNA array. Control (untreated and untreated) and virus transfected and 5-Aza-dC (20 μM) treated cells (pooled colonies) that escaped senescence were harvested. For miRNA microarray, small RNAs (less than 200 nt including precursor and mature miRNAs) were extracted using mirVana miRNA isolation kit (Ambion). Labeled RNA was hybridized with oligonucleotides against human miRs (~500) arrayed on slides (Hokkaido-System Science, Japan), and detected by a scanner (Agilent Technologies, Santa Clara, CA, USA). miRs that showed more than 2 fold change in expression were considered for further analysis.

Cloning of mir-335, expression plasmid. pCXGb-mir-335: a primary mir-335 region was amplified from human genomic DNA by PCR using the following primers: 5′-AACCTCGAGTTCAAGCCTTCATTGGTTTAATCTTTACACAGGC-3′ and 5′-AAAGATATCTGATGACATGAAGCCTTATCTTACACATTAG-3′. The PCR product was digested with SalI and EcoRV and introduced into pCXGb as described earlier.

Senescence-associated β-galactosidase assay (SA-β-gal). SA-β-gal detection kit (Cell Signaling Technology, Danvers, MA, USA) was used following manufacturer’s instructions. Cells showing blue staining were considered positive and counted under the microscope quantitation from three independent experiments was performed.

Flow cytometry. Control and transfected cells were harvested by trypsin (0.25%). Cell pellets were washed with cold PBS and then added drop-wise to pre-chilled 70% ethanol. The fixed cells were centrifuged at 800 X g for 5 min at 4 °C, washed with cold PBS twice and then re-suspended in 0.25 ml PBS. The cells suspensions were treated with RNase A at 37 °C for 1 h followed by brief centrifugation to discard supernatant. Cells were re-suspended in 200 μl of Cell Cycle Guava reagent (Millipore, Billerica, MA, USA), incubated for 30 min in dark and analyzed by EasyCyte Guava cytometer (Millipore). The data were further analyzed using FlowJo software.

Cell viability, proliferation and colony forming assay. Equal number of control and transfected cells were plated in 96-well plates. After 48 h of incubation at 37 °C, 100 μl of MTT (Sigma-Aldrich) in PBS (5 mg/ml) was added to each well. After 4 h of incubation at 37 °C, the supernatant was discarded and the precipitate was dissolved with 100 μl of dimethyl sulfoxide (DMSO). Plates were then read on a microplate reader (infinite M200 PRO, TECAN) at 570 nm.

For cell proliferation assay, control and transfected cells were harvested by trypsin (0.25%). Cell pellets were washed with cold PBS and then added drop-wise to pre-chilled 70% ethanol. The fixed cells were centrifuged at 800 X g for 5 min at 4 °C, washed with cold PBS twice and then re-suspended in 0.25 ml PBS. The cells suspensions were treated with RNase A at 37 °C for 1 h followed by brief centrifugation to discard supernatant. Cells were re-suspended in 200 μl of Cell Cycle Guava reagent (Millipore, Billerica, MA, USA), incubated for 30 min in dark, and analyzed by EasyCyte Guava cytometer (Millipore). The data were further analyzed using FlowJo software.

For cell proliferation assay, control and transfected cells were plated onto 12-well plates. Cells were harvested and counted in triplicates at the indicated time point using TC20TM Automated Cell Counter (Bio-Rad, Hercules, CA, USA), with trypan blue exclusion to identify viable cells. Growth curves were generated for each cell line from three independent experiments.

For long-term cell viability and proliferation, colony forming assay was performed. 500 cells were plated in 6-well plate and left to form colonies for the next 10–15 days with a regular change of medium on every third day. Colonies were fixed with pre-chilled methanol/acetone (1/1, v/v) 10 min on ice, stained with 0.1% crystal violet solution, photographed and counted.

Cloning of pMIR-CARF-3′ UTR plasmid. CARF-3′ untranslated region (UTR) was amplified by PCR (initial 10 min denaturation step at 98 °C followed by 30 cycles of 98 °C for 30 s, 55 °C for 30 s and 72 °C for 30 s, with a final annealing step at 72 °C for 10 min) using human genomic DNA with primers: 5′-GTGAAGAGTTTAAACTGTGTCCAAAATATCACTGC-3′ and 5′-ACTAGTACTAGTCTAACAGACACGTTCAAC-3′. The PCR product was digested with PmeI and SpeI, and then introduced into pMIR-REPORTTM Luciferase plasmid (Applied Biosystems, Forster, CA, USA) between these two sites.

Luciferase reporter assay. The pGL4-p53-3′ UTR and pGL4-p21-3′ UTR were generously provided by Dr. Chae-Ok Yun (Hanyang University, Seoul, South Korea). U2OS control and miR-335 transfected cells were transfected with 1 μg of luciferase constructs (pGL4-p53-3′ UTR, pGL4-p21-3′ UTR or pMIR-CARF-3′ UTR), 100 ng of control vector oligonucleotide (pRL-TK or pMIR-REPORTTM β-gal control plasmid) using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA). After 24–48 h, luciferase activity was measured using a dual luciferase reporter
assay system and β-gal enzyme system (Promega, Madison, WI, USA) following the manufacturer’s protocol. Experiments were carried out in triplicate and repeated at least three times.

RNA extraction and real-time qRT-PCR. Total RNA was isolated from cells using the RNeasy mini kit (Qiajen, Standford Valencia, CA, USA). The concentration and purity of RNA were determined by ultraviolet spectrophotometry (A260/A280 > 1.9) using NanoDrop ND-1000 (Nanodrop Technologies, Wilmington, DE, USA).

Equal amount of RNA were used for reverse transcription following the protocol of QuantiTect Reverse Transcription Kit (Qiajen). The real-time qRT-PCR (50 °C for 2 min; 95 °C for 10 min, 40 cycles of 95 °C for 15 s, 60 °C for 1 min; and 72 °C for 30 s) was performed using SYBR® Select Master Mix (Applied Biosystems in triplicate on the Eco™ real time system (Illumina, San Diego, CA USA). The real-time qRT-PCR results were analyzed and expressed as relative expression of threshold cycle value that was then converted to x-fold changes (2^−ΔΔCt) following manufacturer’s instructions and primer sets (listed in Table 1).

For miR-335 expression analysis, the corresponding miR-335 (Assay ID: 000546) and RNU6B (Assay ID: 001093) primers and TaqMan® MicroRNA assay was performed following the manufacturer’s instructions (Applied Biosystems). RNU6B served as an endogenous control for normalization. Real-time qRT-PCR was conducted at 95 °C for 10 min, 40 cycles of 95 °C for 15 s and 65 °C for 1 min. Stem loop sequence of miR-335 and RNU6B are described in Table 2.

Western blotting. Cells were harvested using RIPA buffer (Thermo Scientific, Waltham, MA, USA) supplemented with a protease inhibitor cocktail (Roche). The protein concentrations were determined by using the Pierce BCA Protein Assay Kit (Thermo Scientific). Western blotting was performed as described earlier using following antibodies: Anti-p16 (C-20), anti-p21 (C-19), anti-p53 (DO-1), anti-MDM2 (HDM2-232), anti-Cdk4 (C-22), anti-E2F (MH5), anti-GFP (B-2) (Santa Cruz, CA, USA), anti-Phospho-Rb (Ser780), anti-Rb (4H1) (Cell Signaling, Danvers, MA, USA) and anti-CARF (FLA-10)52. Anti-β-actin antibody (AC-15) (Abcam, Cambridge, MA, USA) was used as an internal loading control. All the experiments were performed in triplicate at least three times.

Immunostaining. Cells were cultured on a glass coverslip placed in a 12-well culture dish. For immunostaining, cells were washed (cold PBS), fixed (pre-chilled methanol/acetone (1:1) mixture for 10 min), permeabilized (0.5% Triton X-100 in PBS for 10 min), blocked (0.2% BSA/PBS for 1 h) and were then incubated with specific antibody (as described above) for overnight at 4 °C. They were incubated with Alexa-594-conjugated goat anti-mouse or anti-rabbit (Molecular Probes, Invitrogen) secondary antibodies after washings ( thrice) with 0.2%

| Gene (human) | Sequence (5′-3′) |
|-------------|-----------------|
| p21 \( \text{WAF1} \) forward | GAGGCCGGGATGAGTTGGGAGGAG |
| p21 \( \text{WAF1} \) reverse | CAGGGCTCCTGCAGCAGGAC |
| CDK4 forward | TGGAACCTTCCTCTGCTG |
| CDK4 reverse | TACATCGAGGACCTCAGT |
| p16 \( \text{INK4a} \) (1) forward | CCAAGACCGAAGAATGTTA |
| p16 \( \text{INK4a} \) (1) reverse | ACCAGGGTGCTCAGGAG |
| p16 \( \text{INK4a} \) (2) forward | GAAGGCTCCTGAGACATCCC |
| p16 \( \text{INK4a} \) (2) reverse | CCCCTGAGACCTTCCGGTAC |
| p16 \( \text{INK4a} \) (3) forward | CCCCTGAGGACCTCAGGAG |
| p16 \( \text{INK4a} \) (3) reverse | AGGCCGCTCCCTTTCCATTG |
| Rb forward | GGAGGCAAGCCCTCTCTTAAACC |
| Rb reverse | TTTCTGGTTTGTATCCG |
| p53 forward | AACAGTTCTTCATGGGGGCG |
| p53 reverse | AGGACAGGACACAAACACCCAC |
| HDM2 forward | TAGTAGGCTCCTCTTCTGATGA |
| HDM2 reverse | CACTTTCCTCCGCTCTGATAC |
| CARF forward | TCAAAGTGACAGATCTCCTCA |
| CARF reverse | CGTTGACCTTGTGCTT |
| 18s forward | CAGGGTGATGATCAGT |
| 18s reverse | CCTCCAGTGGATCTCTGTTA |

Table 1. qRT-PCR primer set sequences.

| Gene | Sequence (5′-3′) |
|------|-----------------|
| miR-335 | UGUUUUGAGCGGGGUCAAGGGCAUAAGGGAAAAAGUUGUCUAUAACGGUUUAAGUUGCCUG |
| RNU6B | GCCAGGGTGACAGCAAATTTCGGAAGCCCATCATATTTT |

Table 2. Stem loop sequence.
Triton X-100 in PBS. Cancer formation was defined as significant (*) using 4 mice in each group. Volume of the subcutaneous tumors was calculated as $V = \frac{L \times W^2}{2}$, where $L$ was length and $W$ was the width of the tumor, respectively. Protocols for animal experiments were approved by the Animal Care and Use Committee, Institute of Laboratory Animal Science of Peking Union Medical College (ILAS-PG-2014-018).

Statistical analysis. All experiments were carried out more than three times, and data were expressed as mean ± standard deviation (SD). Data were represented with respect to the control that were set either at 100 or 1 as shown. Two-tailed Student’s t-test or nonparametric Mann-Whitney U-test, whichever was applicable, was used to determine the degree of significance between the control and experimental sample. Statistical significance was defined as significant (‘p-value ≤ 0.05), very significant (‘p-value ≤ 0.01) and very very significant (‘p-value ≤ 0.001).

References

1. Hu, J. et al. Identification of microRNA-93 as a functional dysregulated miRNA in triple-negative breast cancer. *Tumour Biol* 36, 251–258, doi:10.1007/s13277-014-2611-8 (2014).

2. Pignot, G. et al. microRNA expression profile in a large series of bladder tumors: identification of a 3-miRNA signature associated with aggressiveness of muscle-invasive bladder cancer. *Int J Cancer* 132, 2479–2491, doi:10.1002/ijc.27494 (2013).

3. Zhang, D. G., Zheng, J. N. & Shi, D. S. P53/microRNA-34-induced metabolic regulation: new opportunities in anticancer therapy. *Mol Cancer* 13, 115, doi:10.1186/1476-4598-13-115 (2014).

4. Wadlwa, R., Kaul, S. C. & Mitsui, Y. Cellular mortality to immortalization: a non-thermal perspective. *Cell Struct Funct* 19, 1–10 (1994).

5. Campisi, J. Cancer, aging and cellular senescence. *In Vivo* 14, 183–188 (2000).

6. Johnson, C., Warnoes, M. O., Shen, X. & Locasale, J. W. Epigenetics and cancer metabolism. *Cancer Lett* 356, 309–314, doi:10.1016/j.canlet.2013.09.043 (2015).

7. Ma, X., Choudhury, S. N., Hua, X., Dai, Z. & Li, Y. Interaction of the oncogenic miR-21 microRNA and the p53 tumor suppressor pathway. *Carcinogenesis* 34, 1216–1223, doi:10.1093/carcin/bgt044 (2013).

8. Tang, T. et al. MicroRNA-182 plays an onco-miRNA role in cervical cancer. *Gynecol Oncol* 129, 199–208, doi:10.1016/j.ygyno.2012.12.043 (2013).

9. Zhang, J. et al. Loss of microRNA-143/145 disturbs cellular growth and apoptosis of human epithelial cancers by impairing the MDM2-p53 feedback loop. *Oncoogene* 32, 61–89, doi:10.1038/onc.2012.28 (2013).

10. Glud, M. et al. MicroRNA miR-125b induces senescence in human melanoma cells. *Melanoma Res* 21, 253–256, doi:10.1097/CMR.0b013e32834533b3 (2011).

11. Bai, X. Y. et al. miR-335 and miR-34a Promote renal senescence by suppressing mitochondrial antioxidative enzymes. *J Am Soc Nephrol* 22, 1252–1261, doi:10.1681/ASN.2010050367 (2011).

12. Gao, Y. et al. MiR-335 acts as a candidate tumor suppressor in prostate cancer. *Pathol Oncol Res* 19, 529–537, doi:10.1007/s11523-013-9613-5 (2013).

13. Iqbal, N., Mei, J., Liu, J. & Skapek, S. X. miR-34a is essential for p19(Arf)-driven cell cycle arrest. *Cell Cycle* 12, 2537–2546, doi:10.1080/15352990.2013.815700 (2013).

14. Leite, K. R. et al. MicroRNA 100: a context-dependent miRNA in prostate cancer. *Carcinogenesis* 34, 3537–3546, doi:10.1038/onc.2012.28 (2013).

15. Novello, C. et al. p53-dependent activation of microRNA-34a in response to etoposide-induced DNA damage in osteosarcoma cell lines not impaired by dominant negative p53 expression. *PLoS One* 9, e114757, doi:10.1371/journal.pone.0114757 (2014).

16. Touw, I. P. & Erkeland, S. J. Retroviral insertion mutagenesis in mice as a comparative oncogenicomics tool to identify disease genes in human leukemia. *Mol Ther* 15, 13–19, doi:10.1038/sj.mt.6300040 (2007).

17. Dohi, O. et al. Epigenetic silencing of miR-335 and its host gene MEST in hepatocellular carcinoma. *Int J Oncol* 42, 411–418, doi:10.3892/ijo.2012.7124 (2013).

In vivo tumor formation assay. Balb/c nude mice (4 weeks old, female) were provided by the Institute of Laboratory Animal Science of Peking Union Medical College. Cells (A549 and A549-miR335 transfected cells) were injected into the nude mice subcutaneously (5 × 10^5 suspended in 0.2 ml of growth medium). Tumor formation and mice health (body weight) was monitored every alternate day. The experiment was repeated twice, using 4 mice in each group. Volume of the subcutaneous tumors was calculated as $V = \frac{L \times W^2}{2}$, where $L$ was length and $W$ was the width of the tumor, respectively. Protocols for animal experiments were approved by the Animal Care and Use Committee, Institute of Laboratory Animal Science of Peking Union Medical College (ILAS-PG-2014-018).
Tumor suppressor activity of miRNA-335 and its new target CARF.

Loss-of-function screening to identify miRNAs involved in senescence: Mech Ageing Dev 130, 18–23, doi: 10.1016/j.mad.2008.05.002 (2009).

Cheung, C. T., Hasan, M. K., Wadlawa, N., Kaul, S. C. & Wadhwa, R. CARF: an emerging regulator of p53 tumor suppressor and senescence pathway. Mech Ageing Dev 130, 18–23, doi: 10.1016/j.mad.2008.05.002 (2009).

Cheung, C. T., Singh, R., Kalra, R. S., Kaul, S. C. & Wadhwa, R. Collaborator of ARF (CARF) regulates proliferative fate of human cells by dose-dependent regulation of DNA damage signaling. J Biol Chem 289, 18258–18269, doi: 10.1074/jbc.M114.547208 (2014).

Hasan, M. K. et al. CARF (collaborator of ARF) interacts with HDM2: evidence for a novel regulatory feedback regulation of CARF-p53-HDM2-p21WAF1 pathway. Int J Oncol 32, 663–671 (2008).

Kalra, R. S. et al. CARF (Collaborator of ARF) overexpression in p53-deficient cells promotes carcinogenesis. Mol Oncol 9, 1877–1889, doi: 10.1016/molonc.2015.07.003 (2015).

Cheung, C. T. et al. Molecular characterization of apoptosis induced by CARF silencing in human cancer cells. Cell Death Differ 18, 589–601, doi: 10.1038/cdd.2010.129 (2011).

Chen, C., Wu, Q. C., Zhang, Z. Q., Yao, D. K. & Zhu, L. Loss of expression of miR-335 is implicated in hepatic stellate cell migration and activation. Exp Cell Res 317, 1714–1725, doi: 10.1016/j.yexcr.2011.05.001 (2011).

Tome, M. et al. miR-335 correlates with senescence/aging in human mesenchymal stem cells and inhibits their therapeutic actions through inhibition of AP-1 activity. Stem Cells 32, 2229–2244, doi: 10.1002/stem.1699 (2014).

Png, K. J. et al. MicroRNA-335 inhibits tumor reinitiation and is silenced through genetic and epigenetic mechanisms in human breast cancer. Genes Dev 25, 226–231, doi: 10.1101/gad.1974211 (2011).

Tome, M. et al. miR-335 orchestrates cell proliferation, migration and differentiation in human mesenchymal stem cells. Cell Death Differ 18, 985–995, doi: 10.1038/cdd.2010.167 (2011).

Lynch, J. et al. Metastasis suppressor microRNA-335 targets the formiminogen of actin nucleators. PLoS One 8, e78428, doi: 10.1371/journal.pone.0078428 (2013).

Gong, M. et al. miR-335 inhibits small cell lung cancer bone metastases via IGFR-IR and RANKL pathways. Mol Cancer Res 12, 101–110, doi: 10.1158/1541-7786.MCR-13-0136 (2014).

Gao, L. et al. MiR-335 functions as a tumor suppressor in pancreatic cancer by targeting OCT4. Tumour Biol 35, 8309–8318, doi: 10.1007/s13277-014-2092-9 (2014).

Cheng, Q. et al. PAX6, a novel target of miR-335, inhibits cell proliferation and invasion in glioma cells. Mol Med Rep 10, 399–404, doi: 10.3892/mmr.2014.2150 (2014).

Cao, J. et al. miR-335 represents an invasion suppressor gene in ovarian cancer by targeting Bcl-w. Oncol Rep 30, 701–706, doi: 10.3892/or.2013.2482 (2013).

Lynch, J. et al. MiRNA-335 suppresses neuroblastoma cell invasiveness by direct targeting of multiple genes from the non-canonical TGF-beta signalling pathway. Carcinogenesis 33, 976–985, doi: 10.1093/carcin/bgs114 (2012).

Li, H. et al. The clinical significance of downregulation of mir-124-3p, mir-146a-5p, mir-155-5p and mir-335-5p in gastric cancer tumorigenesis. Int J Oncol 45, 197–208, doi: 10.3892/ijo.2014.2415 (2014).

Sun, Z. et al. MicroRNA-335 inhibits invasion and metastasis of colorectal cancer by targeting ZEB2. Med Oncol 31, 982, doi: 10.1007/s12032-014-0982-8 (2014).

Wadhwa, R. et al. Use of a randomized hybrid ribozyme library for identification of genes involved in muscle differentiation. J Biol Chem 279, 51622–51629, doi: 10.1074/jbc.M407428200 (2004).

Kato, Y. et al. Real-time functional imaging for monitoring miR-133 during myogenic differentiation. Int J Biochem Cell Biol 41, 2225–2231, doi: 10.1016/j.biocel.2009.04.018 (2009).

Yoon, A. R. et al. MicroRNA-296 is enriched in cancer cells and downregulates p21WAF1 mRNA expression via interaction with its 3′ untranslated region. Nucleic Acids Res 39, 8078–8091, doi: 10.1093/nar/gkr492 (2011).

Hasan, M. K. et al. Alternative reading frame protein (ARF)-independent function of CARF (collaborator of ARF) involves its interactions with p53: evidence for a novel p53-activation pathway and its negative feedback control. Biochem J 380, 605–610 (2004).

Acknowledgements

The authors thank Nashi Widodo for valuable support. ZK was supported by Pelotonia Postdoctoral Fellowship, The Ohio State University. This work was supported by KAKENHI Grant Number 26249127 (to YK).

Author Contributions

Y.Y., R.G., Z.K. and L.L. conducted the experiments and analyzed data. Y.K., Z.Z. and J.G. participated in its design and coordination, and helped to draft the manuscript. S.C.K. and R.W. conceived the study and wrote the manuscript.

Additional Information

Supplementary information accompanies this paper at http://www.nature.com/srep

Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Yu, Y. et al. Loss-of-function screening to identify miRNAs involved in senescence: Tumor suppressor activity of miRNA-335 and its new target CARF. Sci. Rep. 6, 30185; doi: 10.1038/srep30185 (2016).

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/